Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 6464 entries
Sorted by: Best Match Show Resources per page
Mortality due to cirrhosis and liver cancer in the United States, 1999-2016: observational study

Build and Broaden 3.0 AND Program Evaluation

Parikh ND, Tapper EB.
GSID: AzKHFATD-DwJ
EB Tapper, ND Parikh - bmj, 2018 - bmj.com

Objective To describe liver disease related mortality in the United States during 1999-2016 by age group, sex, race, cause of liver disease, and geographic region. Design Observational cohort study. Setting Death certificate data from the Vital Statistics Cooperative, and...

Cite
Tapper, E. B., & Parikh, N. D. (2018). Mortality due to cirrhosis and liver cancer in the United States, 1999-2016: observational study. bmj, 362.
Tapper, Elliot B., and Neehar D. Parikh. "Mortality due to cirrhosis and liver cancer in the United States, 1999-2016: observational study." bmj 362 (2018).
Copy Download .nbib Format: MLA
[Radioisotope scanning of liver cancer].

Nihon rinsho. Japanese journal of clinical medicine

Narabayashi K, Tominaga A, Kajita A, Maeda T, Narabayashi I.
PMID: 5627568
Nihon Rinsho. 1967 Oct;25(10):2310-9.

No abstract available.

Cite
Narabayashi K, Tominaga A, Kajita A, et al. [Radioisotope scanning of liver cancer]. Nihon Rinsho. 1967;25(10):2310-9
Narabayashi, K., Tominaga, A., Kajita, A., Maeda, T., & Narabayashi, I. (1967). [Radioisotope scanning of liver cancer]. Nihon rinsho. Japanese journal of clinical medicine, 25(10), 2310-9.
Narabayashi, K, et al. "[Radioisotope scanning of liver cancer]." Nihon rinsho. Japanese journal of clinical medicine vol. 25,10 (1967): 2310-9.
Narabayashi K, Tominaga A, Kajita A, Maeda T, Narabayashi I. [Radioisotope scanning of liver cancer]. Nihon Rinsho. 1967 Oct;25(10):2310-9. Japanese. PMID: 5627568.
Copy Download .nbib Format: NLM
Anti-proliferative effects of raw and steamed extracts of Panax notoginseng and its ginsenoside constituents on human liver cancer cells.

Chinese medicine

Toh DF, Patel DN, Chan EC, Teo A, Neo SY, Koh HL.
PMID: 21255464
Chin Med. 2011 Jan 24;6:4. doi: 10.1186/1749-8546-6-4.

BACKGROUND: Panax notoginseng is a potential source of anticancer compounds. This study aims to investigate the effects of steaming on the chemical profile of P. notoginseng and the anti-proliferative effects of P. notoginseng on liver cancer cells.METHODS: Samples of...

Cite
Toh DF, Patel DN, Chan EC, et al. Anti-proliferative effects of raw and steamed extracts of Panax notoginseng and its ginsenoside constituents on human liver cancer cells. Chin Med. 2011;6:4doi: 10.1186/1749-8546-6-4.
Toh, D. F., Patel, D. N., Chan, E. C., Teo, A., Neo, S. Y., & Koh, H. L. (2011). Anti-proliferative effects of raw and steamed extracts of Panax notoginseng and its ginsenoside constituents on human liver cancer cells. Chinese medicine, 64. https://doi.org/10.1186/1749-8546-6-4
Toh, Ding-Fung, et al. "Anti-proliferative effects of raw and steamed extracts of Panax notoginseng and its ginsenoside constituents on human liver cancer cells." Chinese medicine vol. 6 (2011): 4. doi: https://doi.org/10.1186/1749-8546-6-4
Toh DF, Patel DN, Chan EC, Teo A, Neo SY, Koh HL. Anti-proliferative effects of raw and steamed extracts of Panax notoginseng and its ginsenoside constituents on human liver cancer cells. Chin Med. 2011 Jan 24;6:4. doi: 10.1186/1749-8546-6-4. PMID: 21255464; PMCID: PMC3037355.
Copy Download .nbib Format: NLM
Prognostic Significance of BCL9 Expression in Hepatocellular Carcinoma.

Korean journal of pathology

Hyeon J, Ahn S, Lee JJ, Song DH, Park CK.
PMID: 23667372
Korean J Pathol. 2013 Apr;47(2):130-6. doi: 10.4132/KoreanJPathol.2013.47.2.130. Epub 2013 Apr 24.

BACKGROUND: BCL9 enhances β-catenin-mediated transcriptional activity regardless of the mutational status of the Wnt signaling components and increases the cell proliferation, migration, invasion, and metastatic potential of tumor cells. The goal of this study was to elucidate the prognostic...

Cite
Hyeon J, Ahn S, Lee JJ, et al. Prognostic Significance of BCL9 Expression in Hepatocellular Carcinoma. Korean J Pathol. 2013;47(2):130-6doi: 10.4132/KoreanJPathol.2013.47.2.130.
Hyeon, J., Ahn, S., Lee, J. J., Song, D. H., & Park, C. K. (2013). Prognostic Significance of BCL9 Expression in Hepatocellular Carcinoma. Korean journal of pathology, 47(2), 130-6. https://doi.org/10.4132/KoreanJPathol.2013.47.2.130
Hyeon, Jiyeon, et al. "Prognostic Significance of BCL9 Expression in Hepatocellular Carcinoma." Korean journal of pathology vol. 47,2 (2013): 130-6. doi: https://doi.org/10.4132/KoreanJPathol.2013.47.2.130
Hyeon J, Ahn S, Lee JJ, Song DH, Park CK. Prognostic Significance of BCL9 Expression in Hepatocellular Carcinoma. Korean J Pathol. 2013 Apr;47(2):130-6. doi: 10.4132/KoreanJPathol.2013.47.2.130. Epub 2013 Apr 24. PMID: 23667372; PMCID: PMC3647125.
Copy Download .nbib Format: NLM
Pre-operatively misdiagnosed undifferentiated embryonal sarcoma of the liver: analysis of 16 cases.

Annals of translational medicine

Li Y, Cai Q, Jia N, Chen D, Lu L, Cheng H.
PMID: 26807408
Ann Transl Med. 2015 Dec;3(22):353. doi: 10.3978/j.issn.2305-5839.2015.11.20.

BACKGROUND: To investigate the clinical features of undifferentiated embryonal sarcoma of the liver (UESL) to improve its preoperative diagnostic accuracy.METHODS: The clinical, imaging, and histopathologic findings of 16 UESL patients whose disease was pathologically confirmed but preoperatively misdiagnosed were...

Cite
Li Y, Cai Q, Jia N, et al. Pre-operatively misdiagnosed undifferentiated embryonal sarcoma of the liver: analysis of 16 cases. Ann Transl Med. 2015;3(22):353doi: 10.3978/j.issn.2305-5839.2015.11.20.
Li, Y., Cai, Q., Jia, N., Chen, D., Lu, L., & Cheng, H. (2015). Pre-operatively misdiagnosed undifferentiated embryonal sarcoma of the liver: analysis of 16 cases. Annals of translational medicine, 3(22), 353. https://doi.org/10.3978/j.issn.2305-5839.2015.11.20
Li, Yanzhuo, et al. "Pre-operatively misdiagnosed undifferentiated embryonal sarcoma of the liver: analysis of 16 cases." Annals of translational medicine vol. 3,22 (2015): 353. doi: https://doi.org/10.3978/j.issn.2305-5839.2015.11.20
Li Y, Cai Q, Jia N, Chen D, Lu L, Cheng H. Pre-operatively misdiagnosed undifferentiated embryonal sarcoma of the liver: analysis of 16 cases. Ann Transl Med. 2015 Dec;3(22):353. doi: 10.3978/j.issn.2305-5839.2015.11.20. PMID: 26807408; PMCID: PMC4701533.
Copy Download .nbib Format: NLM
[In Process Citation].

Orvosi hetilap

Horváth G, Gerlei Z, Gervain J, Lengyel G, Makara M, Pár A, Rókusz L, Szalay F, Tornai I, Werling K, Hunyady B.
PMID: 26667112
Orv Hetil. 2015 Dec 15;156:25-36. doi: 10.1556/OH.2015.30331.

Diagnosis and treatment of HBV/HDV infection means for the patient to be able to maintain working capacity, to increase quality of life, to prevent cancer, and to prolong life expectancy, while society benefits from eliminating the chances of further...

Cite
Horváth G, Gerlei Z, Gervain J, et al. A hepatitis B- és D-vírus-fertőzés diagnosztikája, antivirális kezelése. Magyar konszenzusajánlás. Érvényes: 2015. szeptember 12-től. [In Process Citation]. Orv Hetil. 2015;156:25-36doi: 10.1556/OH.2015.30331.
Horváth, G., Gerlei, Z., Gervain, J., Lengyel, G., Makara, M., Pár, A., Rókusz, L., Szalay, F., Tornai, I., Werling, K., & Hunyady, B. (2015). A hepatitis B- és D-vírus-fertőzés diagnosztikája, antivirális kezelése. Magyar konszenzusajánlás. Érvényes: 2015. szeptember 12-től. [In Process Citation]. Orvosi hetilap, 15625-36. https://doi.org/10.1556/OH.2015.30331
Horváth, Gábor, et al. "A hepatitis B- és D-vírus-fertőzés diagnosztikája, antivirális kezelése. Magyar konszenzusajánlás. Érvényes: 2015. szeptember 12-től." [In Process Citation]. Orvosi hetilap vol. 156 (2015): 25-36. doi: https://doi.org/10.1556/OH.2015.30331
Horváth G, Gerlei Z, Gervain J, Lengyel G, Makara M, Pár A, Rókusz L, Szalay F, Tornai I, Werling K, Hunyady B. A hepatitis B- és D-vírus-fertőzés diagnosztikája, antivirális kezelése. Magyar konszenzusajánlás. Érvényes: 2015. szeptember 12-től. [In Process Citation]. Orv Hetil. 2015 Dec 15;156:25-36. doi: 10.1556/OH.2015.30331. Hungarian. PMID: 26667112.
Copy Download .nbib Format: NLM
Use of Percutaneous Sonographically Guided Microwave Ablation Therapy to Treat Inoperable Malignant Liver Tumours.

The West Indian medical journal

Wang QC, Cheng W, Zhang L, Sun YX, Xing CH.
PMID: 26360677
West Indian Med J. 2015 Mar;64(2):76-80. doi: 10.7727/wimj.2014.132. Epub 2015 Jul 23.

AIMS: Microwave ablation (MWA) is a technique which is used to destroy tumours and soft tissues by using microwave energy to create coagulation and localized tissue necrosis. It is used to treat the tumours which are considered to be...

Cite
Wang QC, Cheng W, Zhang L, et al. Use of Percutaneous Sonographically Guided Microwave Ablation Therapy to Treat Inoperable Malignant Liver Tumours. West Indian Med J. 2015;64(2):76-80doi: 10.7727/wimj.2014.132.
Wang, Q. C., Cheng, W., Zhang, L., Sun, Y. X., & Xing, C. H. (2015). Use of Percutaneous Sonographically Guided Microwave Ablation Therapy to Treat Inoperable Malignant Liver Tumours. The West Indian medical journal, 64(2), 76-80. https://doi.org/10.7727/wimj.2014.132
Wang, Q C, et al. "Use of Percutaneous Sonographically Guided Microwave Ablation Therapy to Treat Inoperable Malignant Liver Tumours." The West Indian medical journal vol. 64,2 (2015): 76-80. doi: https://doi.org/10.7727/wimj.2014.132
Wang QC, Cheng W, Zhang L, Sun YX, Xing CH. Use of Percutaneous Sonographically Guided Microwave Ablation Therapy to Treat Inoperable Malignant Liver Tumours. West Indian Med J. 2015 Mar;64(2):76-80. doi: 10.7727/wimj.2014.132. Epub 2015 Jul 23. PMID: 26360677; PMCID: PMC4696636.
Copy Download .nbib Format: NLM
Genomic variants link to hepatitis C racial disparities.

Oncotarget

Yeh MM, Boukhar S, Roberts B, Dasgupta N, Daoud SS.
PMID: 28938650
Oncotarget. 2017 Aug 01;8(35):59455-59475. doi: 10.18632/oncotarget.19755. eCollection 2017 Aug 29.

Chronic liver diseases are one of the major public health issues in United States, and there are substantial racial disparities in liver cancer-related mortality. We previously identified racially distinct alterations in the expression of transcripts and proteins of hepatitis...

Cite
Yeh MM, Boukhar S, Roberts B, et al. Genomic variants link to hepatitis C racial disparities. Oncotarget. 2017;8(35):59455-59475doi: 10.18632/oncotarget.19755.
Yeh, M. M., Boukhar, S., Roberts, B., Dasgupta, N., & Daoud, S. S. (2017). Genomic variants link to hepatitis C racial disparities. Oncotarget, 8(35), 59455-59475. https://doi.org/10.18632/oncotarget.19755
Yeh, Matthew M, et al. "Genomic variants link to hepatitis C racial disparities." Oncotarget vol. 8,35 (2017): 59455-59475. doi: https://doi.org/10.18632/oncotarget.19755
Yeh MM, Boukhar S, Roberts B, Dasgupta N, Daoud SS. Genomic variants link to hepatitis C racial disparities. Oncotarget. 2017 Aug 01;8(35):59455-59475. doi: 10.18632/oncotarget.19755. eCollection 2017 Aug 29. PMID: 28938650; PMCID: PMC5601746.
Copy Download .nbib Format: NLM
Serum 25-hydroxyvitamin D deficiency and hepatic encephalopathy in chronic liver disease.

World journal of hepatology

Vidot H, Potter A, Cheng R, Allman-Farinelli M, Shackel N.
PMID: 28443156
World J Hepatol. 2017 Apr 08;9(10):510-518. doi: 10.4254/wjh.v9.i10.510.

AIM: To investigate the relationship between 25-hydroxyvitamin D (25-OHD) deficiency and hepatic encephalopathy (HE) in patients with chronic liver disease (CLD).METHODS: A retrospective analysis of the results of 392 adult patients with chronic liver disease who were assessed for...

Cite
Vidot H, Potter A, Cheng R, et al. Serum 25-hydroxyvitamin D deficiency and hepatic encephalopathy in chronic liver disease. World J Hepatol. 2017;9(10):510-518doi: 10.4254/wjh.v9.i10.510.
Vidot, H., Potter, A., Cheng, R., Allman-Farinelli, M., & Shackel, N. (2017). Serum 25-hydroxyvitamin D deficiency and hepatic encephalopathy in chronic liver disease. World journal of hepatology, 9(10), 510-518. https://doi.org/10.4254/wjh.v9.i10.510
Vidot, Helen, et al. "Serum 25-hydroxyvitamin D deficiency and hepatic encephalopathy in chronic liver disease." World journal of hepatology vol. 9,10 (2017): 510-518. doi: https://doi.org/10.4254/wjh.v9.i10.510
Vidot H, Potter A, Cheng R, Allman-Farinelli M, Shackel N. Serum 25-hydroxyvitamin D deficiency and hepatic encephalopathy in chronic liver disease. World J Hepatol. 2017 Apr 08;9(10):510-518. doi: 10.4254/wjh.v9.i10.510. PMID: 28443156; PMCID: PMC5387363.
Copy Download .nbib Format: NLM
Clinical Presentation, Risk Factors, and Treatment Modalities of Hepatocellular Carcinoma: A Single Tertiary Care Center Experience.

Gastroenterology research and practice

Aljumah AA, Kuriry H, AlZunaitan M, Al Ghobain M, Al Muaikeel M, Al Olayan A, Azzumeea F, Almutairi B, AlAlwan A, AlGhamdi H.
PMID: 27525001
Gastroenterol Res Pract. 2016;2016:1989045. doi: 10.1155/2016/1989045. Epub 2016 Jul 25.

Objective. To investigate the risk factors, clinical characteristics, treatment modalities, and outcomes in Saudi patients with HCC and propose points for early detection of the disease. Methods. Patients were stratified according to underlying risk factors for the development of...

Cite
Aljumah AA, Kuriry H, AlZunaitan M, et al. Clinical Presentation, Risk Factors, and Treatment Modalities of Hepatocellular Carcinoma: A Single Tertiary Care Center Experience. Gastroenterol Res Pract. 2016;2016:1989045doi: 10.1155/2016/1989045.
Aljumah, A. A., Kuriry, H., AlZunaitan, M., Al Ghobain, M., Al Muaikeel, M., Al Olayan, A., Azzumeea, F., Almutairi, B., AlAlwan, A., & AlGhamdi, H. (2016). Clinical Presentation, Risk Factors, and Treatment Modalities of Hepatocellular Carcinoma: A Single Tertiary Care Center Experience. Gastroenterology research and practice, 20161989045. https://doi.org/10.1155/2016/1989045
Aljumah, Abdulrahman A, et al. "Clinical Presentation, Risk Factors, and Treatment Modalities of Hepatocellular Carcinoma: A Single Tertiary Care Center Experience." Gastroenterology research and practice vol. 2016 (2016): 1989045. doi: https://doi.org/10.1155/2016/1989045
Aljumah AA, Kuriry H, AlZunaitan M, Al Ghobain M, Al Muaikeel M, Al Olayan A, Azzumeea F, Almutairi B, AlAlwan A, AlGhamdi H. Clinical Presentation, Risk Factors, and Treatment Modalities of Hepatocellular Carcinoma: A Single Tertiary Care Center Experience. Gastroenterol Res Pract. 2016;2016:1989045. doi: 10.1155/2016/1989045. Epub 2016 Jul 25. PMID: 27525001; PMCID: PMC4976192.
Copy Download .nbib Format: NLM
Survival Benefit of Locoregional Treatment for Hepatocellular Carcinoma with Advanced Liver Cirrhosis.

Liver cancer

Kitai S, Kudo M, Nishida N, Izumi N, Sakamoto M, Matsuyama Y, Ichida T, Nakashima O, Matsui O, Ku Y, Kokudo N, Makuuchi M.
PMID: 27493893
Liver Cancer. 2016 Jul;5(3):175-89. doi: 10.1159/000367765. Epub 2016 May 03.

BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) with decompensated liver cirrhosis (LC) is a life-threatening condition, which is amenable to liver transplantation (LT) as the standard first-line treatment. However, the application of LT can be limited due to a shortage...

Cite
Kitai S, Kudo M, Nishida N, et al. Survival Benefit of Locoregional Treatment for Hepatocellular Carcinoma with Advanced Liver Cirrhosis. Liver Cancer. 2016;5(3):175-89doi: 10.1159/000367765.
Kitai, S., Kudo, M., Nishida, N., Izumi, N., Sakamoto, M., Matsuyama, Y., Ichida, T., Nakashima, O., Matsui, O., Ku, Y., Kokudo, N., Makuuchi, M. (2016). Survival Benefit of Locoregional Treatment for Hepatocellular Carcinoma with Advanced Liver Cirrhosis. Liver cancer, 5(3), 175-89. https://doi.org/10.1159/000367765
Kitai, Satoshi, et al. "Survival Benefit of Locoregional Treatment for Hepatocellular Carcinoma with Advanced Liver Cirrhosis." Liver cancer vol. 5,3 (2016): 175-89. doi: https://doi.org/10.1159/000367765
Kitai S, Kudo M, Nishida N, Izumi N, Sakamoto M, Matsuyama Y, Ichida T, Nakashima O, Matsui O, Ku Y, Kokudo N, Makuuchi M. Survival Benefit of Locoregional Treatment for Hepatocellular Carcinoma with Advanced Liver Cirrhosis. Liver Cancer. 2016 Jul;5(3):175-89. doi: 10.1159/000367765. Epub 2016 May 03. PMID: 27493893; PMCID: PMC4960362.
Copy Download .nbib Format: NLM
How to Improve Therapeutic Ratio in Radiotherapy of HCC.

Liver cancer

Tsai CL, Hsu FM, Cheng JC.
PMID: 27493896
Liver Cancer. 2016 Jul;5(3):210-20. doi: 10.1159/000367767. Epub 2016 May 10.

BACKGROUND: During the past two decades, external-beam radiation technology has substantially changed from traditional two-dimensional to conformal three-dimensional to intensity-modulated planning and stereotactic body radiotherapy (SBRT).SUMMARY: Modern techniques of radiotherapy (RT) are highly focused and capable of delivering an...

Cite
Tsai CL, Hsu FM, Cheng JC. How to Improve Therapeutic Ratio in Radiotherapy of HCC. Liver Cancer. 2016;5(3):210-20doi: 10.1159/000367767.
Tsai, C. L., Hsu, F. M., & Cheng, J. C. (2016). How to Improve Therapeutic Ratio in Radiotherapy of HCC. Liver cancer, 5(3), 210-20. https://doi.org/10.1159/000367767
Tsai, Chiao-Ling, et al. "How to Improve Therapeutic Ratio in Radiotherapy of HCC." Liver cancer vol. 5,3 (2016): 210-20. doi: https://doi.org/10.1159/000367767
Tsai CL, Hsu FM, Cheng JC. How to Improve Therapeutic Ratio in Radiotherapy of HCC. Liver Cancer. 2016 Jul;5(3):210-20. doi: 10.1159/000367767. Epub 2016 May 10. PMID: 27493896; PMCID: PMC4960358.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 6464 entries